TAK 603

BACKGROUND The therapeutic efficacy of the regulation of T helper (Th)-1-predominant immune responses remains to be investigated… (More)

Acute graft-versus-host diseases (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic bone marrow… (More)

A new antirheumatic, TAK-603, shows nonlinear pharmacokinetics in both animals and humans. To elucidate the mechanism of these… (More)

In the course of our studies aimed at obtaining new drugs for treatment of bone and joint diseases, chemical modification of the… (More)

A factor in the dose-dependent pharmacokinetics of ethyl 4-(3, 4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2, 4-triazol-1-yl-methyl… (More)

The disposition of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4- triazol-1-ylmethyl) quinoline-3-carboxylate (CAS 158146… (More)

The metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmeth yl)quinoline -3-carboxylate (1, TAK-603… (More)

A double column-switching high-performance liquid chromatographic (HPLC) method for the determination of concentrations for TAK… (More)

We have shown that TAK-603, a new anti-rheumatic drug, is more effective in animal models in which cellular immunity plays a… (More)

We investigated the pharmacological activities of a newly synthesized anti-rheumatic drug, TAK-603. (1) In vivo: In adjuvant… (More)